Damora Therapeutics: Competitive updates at EHA continue to support the mCALR thesis in ET and MF

研报英文原文证据摘录

Damora Therapeutics: Competitive updates at EHA continue to support the mCALR thesis in ET and MF

Forecast returns

Forecast price appreciation 116.6%

Forecast dividend yield 0.0%

Forecast stock return 116.6%

Market return assumption 9.1%

Forecast excess return 107.5%

Company Description

Galecto, Inc is a biotechnology company developing potentially best-in-class therapeutics

targeting mutant calreticulin (mutCALR) to treat myeloproliferative neoplasms, including

essential thrombocythemia and myelofibrosis. Its pipeline, led by monoclonal antibody DMR-

001, aims to deliver safer, more effective, disease-modifying options for patients with

mutCALR-driven blood cancers.

Valuation Method and Risk Statement

Our valuation is based on a risk-adjusted EV/2035 sales multiple. Key risks include: Clinical

Risk: Drug candidates may fail in clinical trials due to lack of efficacy or safety concerns,

eliminating significant expected value; Regulatory Risk: Approval is subject to complex and

uncertain regulatory processes; delays or rejections can materially impact timelines and

valuations; Financing Risk: Small cap biotech companies often rely on external capital; adverse

market conditions may force dilutive financings or limit access to funding; Competitive Risk:

Larger, better-funded competitors or faster-moving peers may develop superior therapies or

reach the market first; Pricing & Reimbursement Risk: Even approved products may face

pricing pressure, reimbursement challenges, or limited market adoption; Execution Risk:

Limited operating history and lean management teams increase the risk of operational

missteps or strategic errors; Intellectual Property Risk: Patent challenges, expirations, or

inability to secure strong IP protection may erode long term competitive advantage